Factors affecting recurrence and prognosis after R0 resection for colorectal cancer with peritoneal metastasis
- 400 Downloads
Peritoneal metastases (PM) are a well-known poor prognostic factor. The aim of this study was to investigate the factors affecting recurrence and prognosis after R0 resection for colorectal cancer with synchronous peritoneal metastases.
We conducted a multi-institutional retrospective analysis of 72 patients without distant metastases who underwent R0 surgery between 1991 and 2007 for colorectal cancer with PM localized to the adjacent peritoneum. Clinicopathological variables were analyzed for their significance to recurrence and prognosis.
Recurrence was found in 51 patients (70.8 %) after R0 surgery. In logistic regression analyses, lymph node metastasis was shown to be an independent factor affecting recurrence. Non-intensive or no postoperative chemotherapy and eight or fewer dissected lymph nodes were identified as independent poor prognostic factors using the Cox proportional hazards model. Among patients who received postoperative chemotherapy, prognosis was significantly better in those who received intensive adjuvant chemotherapy using camptothecin-11 or oxaliplatin after R0 surgery than in those who received non-intensive chemotherapy. Among 47 patients whose recurrence date was known, 33 patients (70.2 %) experienced recurrence within 18 months after R0 surgery for peritoneal metastases, and hematogenous recurrence was observed significantly more often than peritoneal recurrence.
Harvesting of more than eight lymph nodes and administration of intense adjuvant chemotherapy after R0 surgery are recommended for greater prediction accuracy and improved prognosis. Intensive follow-up should be performed within 18 months after R0 surgery for colorectal cancer with synchronous peritoneal metastases.
KeywordsColorectal cancer Peritoneal metastases R0 surgery Recurrence Prognosis
Compliance with ethical standards
Conflict of interest
All authors declare that they have no conflict of interest with regard to this manuscript.
- 2.Kobayashi H, Enomoto M, Higuchi T, Uetake H, Iida S, Ishikawa T, et al. Validation and clinical use of the Japanese classification of colorectal carcinomatosis: benefit of surgical cytoreduction even without hyperthermic intraperitoneal chemotherapy. Digest Surg. 2010;27(6):473–80.CrossRefGoogle Scholar
- 3.Sobin L, Gospondarowicz M, Wittekind C. TNM Classification of malignant tumors. UICC International Union Against Cancer. 7th ed. New York: Wiley; 2009. p. 100–5.Google Scholar
- 6.Japan Society for Cancer of the Colon and Rectum, editors. Japanese classification of colorectal carcinoma. 2nd ed. Tokyo: Kanehara & Co; 2009.Google Scholar
- 8.Witkamp AJ, de Bree E, Kaag MM, et al. Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. Eur J Cancer (Oxford, England: 1990). 2001;37(8):979–84.CrossRefGoogle Scholar
- 12.Japan Society for Cancer of the Colon and Rectum, editors. JSCCR guidelines 2014 for the treatment of colorectal cancer. Tokyo: Kanehara & Co; 2014.Google Scholar
- 22.Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21(20):3737–43.CrossRefPubMedGoogle Scholar